A Phase 2, Open-Label, Randomized Study of ALT-803, A Fusion Protein Activator of Natural Killer and T Cells, In Combination with Pembrolizumab Vs Pembrolizumab Alone as First-Line Treatment for Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC)
Read more about this trial →← Back to available clinical trials
